FDA Approves Durvalumab for Extensive-Stage Small Cell Lung Cancer - Targeted Oncology

1. FDA Approves Durvalumab for Extensive-Stage Small Cell Lung Cancer  Targeted Oncology
2. AstraZeneca's Lung Cancer Treatment Gets FDA NodAstraZeneca's Lung Cancer Treatment Gets FDA Nod  The New York Times
3. IMFINZI (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer  Odessa American
4. AZ's Imfinzi gets US OK in small cell lung cancer, challenging Tecentriq  PMLiVE
5. FDA approves AZ Imfinzi in new lung cancer use -  pharmaphorum
6. View Full Coverage on Google News